Posted by Michael Wonder on 03 Jul 2023
Zai Lab and argenx announce approval of Vyvgart (efgartigimod alfa injection) for generalised myasthenia gravis in China
30 June 2023 - Zai Lab and argenx today announced that China’s National Medical Products Administration has approved the biologics license application for Vyvgart (efgartigimod alfa injection), a first in class neonatal Fc receptor antagonist, as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
Zai Lab will now work with the National Healthcare Security Administration (NHSA) for National Reimbursement Drug List inclusion to enable broad access for patients.
